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Thromboxane (TX) A2 plays a central role in hemostasis, regulating platelet activation status and vascular tone. We have recently established
that the TPβ isoform of the human TXA2 receptor (TP) undergoes rapid, agonist-induced homologous desensitization of signalling largely through
a G protein-coupled receptor kinase (GRK) 2/3-dependent mechanism with a lesser role for protein kinase (PK) C. Herein, we investigated the
mechanism of desensitization of signalling by the TPα isoform. TPα undergoes profound agonist-induced desensitization of signalling
(intracellular calcium mobilization and inositol 1,4,5 trisphosphate generation) in response to the TXA2 mimetic U46619 but, unlike that of TPβ,
this is independent of GRKs. Similar to TPβ, TPα undergoes partial agonist-induced desensitization that occurs through a GF 109203X-sensitive,
PKC mechanism where Ser145 within intracellular domain (IC)2 represents the key phospho-target. TPα also undergoes more profound sustained
PKC- and PKG-dependent desensitization where Thr337 and Ser331, respectively, within its unique C-tail domain were identified as the phospho-
targets. Desensitization was impaired by the nitric oxide synthase (NOS), soluble guanylyl cyclase (sGC) and PKG inhibitors L-NAME, LY 83583
and KT5823, respectively, indicating that homologous desensitization of TPα involves nitric oxide generation and signalling. Consistent with this,
U46619 led to rapid phosphorylation/activation of endogenous eNOS. Collectively, data herein suggest a mechanism whereby agonist-induced
PKC phosphorylation of Ser145 partially and transiently impairs TPα signalling while PKG- and PKC-phosphorylation at both Ser331 and Thr337,
respectively, within its C-tail domain profoundly desensitizes TPα, effectively terminating its signalling. Hence, in addition to the agonist-
mediated PKC feedback mechanism, U46619-activation of the NOS/sGC/PKG pathway plays a significant role in inducing homologous
desensitization of TPα.
© 2007 Elsevier B.V. Open access under CC BY license.Keywords: Thromboxane receptor; Alpha; Desensitization; Phosphorylation; Nitric oxide; G protein coupled receptor1. Introduction
The prostanoid thromboxane (TX)A2, synthesized through
the sequential actions of cyclooxygenase (COX) 1 and/or COX
2 and TXA2 synthase, plays a critical role in the dynamic
control of hemostasis and vascular tone [1,2] and may induceAbbreviations: C-tail, carboxyl-terminal tail; [Ca2+]i, intracellular calcium;
COX, cyclooxygenase; FBS, foetal bovine serum; GPCR, G protein-coupled
receptor; GRK, G protein-coupled receptor kinase; HA, hemagglutinin; HEK,
human embryonic kidney; IP, prostacyclin receptor; IP3, inositol 1, 4, 5-
trisphosphate; NO, nitric oxide; NOS, nitric oxide synthase; PAGE, polyacryla-
mide gel electrophoresis; PG, prostaglandin; PK, protein kinase; PL, phospholi-
pase; sGC, soluble guanylyl cyclase; TP, TXA2 receptor; TX, thromboxane
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Open access under CC BY license.other diverse cellular responses including mitogenic and/or
hypertrophic growth of vascular smooth muscle [3–5], inhibi-
tion of angiogenesis/neo-vascularization [6–8] and apoptosis of
CD4/CD8+/− immature thymocytes [9]. Additionally, the TXA2
receptor (TP) mediates at least some of the adverse actions of
the isoprostane 8-iso prostaglandin (PG)F2α, generated in
situations of oxidative stress [10,11]. In keeping with these
actions, imbalances in the levels of TXA2 or of its synthase or
receptor (TP) have been implicated in a number of vascular
diseases including thrombosis, unstable angina, bronchial
asthma, hypertension and glomerulonephritis [3–5,12,13].
The TXA2 receptor, or TP, a member of the G protein
coupled receptor superfamily, is primarily coupled to Gq/
phospholipase (PL)Cβ activation and to mobilization of Ca2+
from inositol 1,4,5 trisphosphate-operated intracellular stores
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TPα and TPβ that are identical for their N-terminal 328 amino
acids differing exclusively in their carboxyl terminal (C)-tail
domains [14–16]. Whilst the significance of two receptors for
TXA2 in humans, but not in non-primates, is unknown there is
substantial evidence that they display critical differences in
their signalling and profiles of expression and hence it is
thought likely that they have distinct physiologic/pathophy-
siologic roles [17]. TPα and TPβ exhibit distinct patterns of
expression in a variety of cell/tissue types of vascular origin,
including platelets [18–20] and such differences are due to the
fact that TPα and TPβ are not only products of differential
splicing but are also under the transcriptional control of
distinct promoters within the single human TP gene [21–24].
While TPα and TPβ exhibit identical ligand binding and
coupling to PLCβ [15,25,26], they oppositely regulate
adenylyl cyclase [27] and TPα, but not TPβ, mediates
activation of Gh, leading to PLC activation [28].
A central feature of the general GPCR signal transduction
cascade is the regulation or desensitization of second messenger
generation and signalling that occurs in response to the continued
presence of the ligand, dampening or terminating the specific
cellular response [29,30]. Such desensitization is typically
initiated by GPCR phosphorylation leading to uncoupling of the
receptor from its cognate G-protein [29,30] and may involve
either cross-talk/heterologous desensitization between different
signalling systems or agonist-induced/homologous desensitiza-
tion terminating or modulating the response to the receptor's own
ligand [29,30]. In studies investigating heterologous desensitiza-
tion or cross-talk between TXA2 and other prostanoids, it has been
recently established that while both TP isoforms have evolved to
share a similar mechanism of protein kinase (PK)C-induced
phosphorylation in response to signalling by the EP1 subtype of
the prostaglandin (PG) E2 receptor and by the PGF2α receptor
(FP), those phosphorylations/desensitizations occur at distinct
PKC sites within the unique C-tail domains of TPα and
TPβ, respectively [31,32]. On the other hand, signalling by
TPα, but not TPβ, is subject to prostacyclin and PGD2-mediated
desensitization in a mechanism involving direct protein kinase
(PK) A phosphorylation of TPα at Ser329, the very first residue
within its unique C-tail domain divergent from TPβ [33,34].
Consistent with the latter, TPα, but not the TPβ, is also a target for
nitric oxide (NO)-induced heterologous desensitization of signal-
ling that occurs through direct cGMP-dependent PKG/cGK
phosphorylation at Ser331 also within its C-tail [35]. Collectively,
these latter studies indicate critical differences in the modes of
regulation of signalling by the individual TP isoforms. Specifi-
cally, they point to an essential role for TPα in prostacyclin- and
NO-regulated vascular hemostasis and point to a redundant or an,
as yet, unidentified role for TPβ in this essential physiologic
process [33–35].
As stated, agonist-induced homologous desensitization of
GPCRs is a central mechanismwhereby the cellular responses to
the receptor's own ligand is dynamically modulated and is most
often initiated through phosphorylation of the ligand-engaged,
conformationally active GPCR such as by members of the G
protein-coupled receptor kinases (GRKs) and/or by the second-messenger kinases, such as PKA or PKC [29,30,36]. While both
TP isoforms undergo rapid agonist-induced phosphorylation
in response to TXA2 mimetic U46619 [20,25], TPβ, but not
TPα, is subject to GRK/β-arrestin-dependent internalization
following prolonged agonist exposure [37,38]. We recently
examined the mechanism of agonist-induced homologous
desensitization of signalling and second messenger generation
by TPβ and established that it undergoes two main
mechanisms of desensitization: (i) partial, transient PKC-
dependent desensitization where Ser145 within IC2 was
identified as the PKC phospho-target. In addition, (ii) TPβ
also undergoes more profound and sustained agonist-induced
desensitization involving GRK 2/3-phosphorylation followed
by internalization and we proposed a model whereby
phosphorylation of Ser357 within the C-tail domain led to
the recruitment and orientation of GRK2/3 which, in turn,
facilitated its phosphorylation of Ser239 within IC3 thereby
disrupting Gq coupling by TPβ. Hence, GRK2/3 binding is
dependent on sequences within the unique C-tail domain of
TPβ whilst Gq uncoupling is due to GRK phosphorylation of
Ser239 within IC3 and, to a lesser extent, PKC phosphoryla-
tion of Ser145 within IC2.
In view of these findings, the aim of the current studies was
to investigate the mechanism of homologous desensitization of
signalling by TPα in response to the TXA2 mimetic U46619.
Our data established that TPα is subject to homologous
desensitization of signalling through two key mechanisms
involving receptor phosphorylation: one involving a partial
PKC-dependent mechanism and another involving a profound
and sustained PKG-dependent mechanism engaging NO
signalling and endothelial (e) nitric oxide synthase (NOS)
activation. Unlike that of TPβ, we found no role for the GRK/β-
arrestins in homologous desensitization of TPα. Hence, taken
together, these studies demonstrate critical differences in the
mechanisms of agonist-induced desensitization of signalling
between the TP isoforms and add to the increasing lines of
evidence for distinct physiologic roles for TPα and TPβ in the
mediation and the regulation of signalling by the potent
autocoid TXA2 in humans.
2. Materials and methods
2.1. Materials
SQ29,548 and I-BOP were from the Cayman Chemical Company. Anti-
Gαq (C15; SC-392) antibody was obtained from Santa Cruz Laboratories.
[32P] orthophosphate (8000–9000 Ci/mmol) and [3H]SQ29,548 (50.4 Ci/
mmol) was from NEN Life Sciences Products. [3H] IP3 (20–40 Ci/mmol) was
obtained from American Radiolabelled Chemicals Inc. Anti-HA 101R
monoclonal antibody and anti-HA-3F10-peroxidase conjugated antibody
were obtained from BABCO and from Roche Molecular Biochemicals,
respectively. Monoclonal anti-eNOS antibody (Clone 3) was obtained from
Transduction Laboratories. Anti-phospho-eNOSSer1177(Human)/1179(Bovine) anti-
body was purchased from Cell Signalling Technology. Thrombin was
obtained from Sigma Chemical Co. FURA2/AM and D-myo-inositol 1,4,5-
trisphosphate, 3-deoxyhexasodium salt, U46619, N-[2-((p-bromocinnamyl)
amino)ethyl]-5-isoquino-linesulfonamide, 2HCL (H-89) and 2-[1-(3-dimethy-
laminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)-maleimide (GF 109203X),
NG-Nitro-L-arginine Methyl Ester, Hydrochloride (L-NAME), KT 5823, LY
83583 (6-Anilino-5, 8-quinolinequinone) were obtained from Calbiochem.
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The plasmids pCMV:Gαq, pHM:TPβ, pHM:TPα, pHM:TPΔ328, pHM:
TPαS329A, pHM:TPαS331A, pHM:TPαT337A, pHM:TPαS329,331A, pHM:TPαΔ336
and pRK5:βARK1495–689 have been previously described [10,32,33,35,39].
Fig. 1 illustrates the C-tail sequence of TPα and its mutated variants that
were generated and used in this study. Site-directed mutagenesis was performed
using QuickChangeTM (Stratagene), unless specified otherwise. Mutation of
Ser145 to Ala145 of TPα and TPΔ328 to generate the plasmids pHM:TPαS145A and
pHM:TPS145A, Δ328 was achieved using pHM:TPα and pHM:TPΔ328,
respectively, as templates and sense/antisense primer pair (5′-GC CCG GCG
GTC GCC GCG CAG CGC GCC-3′). Mutation of Ser239 to Ala239 of TPα to
generate pHM:TPαS239 was achieved using pHM:TPα as template and sense/
antisense primer pair (5′-G CGT CCC CGG GAC GCCGAGGTG GAGA-3′).
Conversion of both Ser331,Thr337 to Ala331,Ala337of TPα to generate pHM6:
TPαS331,337A was achieved using pHM:TPαT337A as template and sense/
antisense primer pair (5′-G CCC AGG TCG CTG GCC CTC CAG CCC C-3′).
Mutation of Ser340 to Ala340 of TPα, TPαS331A and TPαT337A to generate pHM:
TPαS340A, pHM:TPαS331,340A and pHM:TPαT337,S340A was achieved using
pHM:TPα, pHM:TPαS331A and pHM:TPαT337A, respectively, as templates
and sense/antisense primer pair (5′-C ACG CAG CGC GCC GGG CTG
CAG TAG G-3’). Mutation of Ser340 to Ala340 of TPαS331,T337A to generate
pHM:TPαS331,T337,S340A was achieved using pHM:TPαS331,T337A as template
and sense/antisense primer pair (5′-CAG CCC CAG CTC GCG CAG CGC
GCC G-3′). Mutation of Ser145 to Ala145 of TPαS331,T337A to generate pHM:
TPαS145,S331,T337A was achieved using pHM:TPαS331,T337A as template and
sense/antisense primer pair (5′-GC CCG GCG GTC GCC GCG CAG CGC
GCC-3′). For each primer pair above, sequence shown corresponds to the sense
primer and in each case the identity of the mutator codon is in boldface italics.
2.3. Cell culture and transfections
Human embryonic kidney (HEK) 293 cells were cultured in minimal
essential medium with Earle's salts (MEM) supplemented with 10% FBS (foetal
bovine serum) and maintained at 37 °C in 5% CO2. The following HEK 293 cell
lines stably over-expressing hemagglutinin (HA) epitope-tagged forms of
TPβ (HEK.TPβ), TPα (HEK.TPα), TPΔ328 (HEK.TPΔ328), TPαS329A (HEK.
TPαS329A), TPαS337A (HEK.TPαT337A), TPαS331A (HEK.TPαS331A),
TPαS329,331A (HEK.TPαS329,331A) and TPαΔ336 have been previously described
[32,33,35].
For transfections, routinely HEK 293 cells were plated in 10 cm dishes at
a density of 2×106 cells/dish in 8 ml media 48 h prior to transfection. Cells
were transiently transfected with 10 μg pADVA [40] and 25 μg of pcDNA-,
pCMV- or pHM-based vectors using the calcium phosphate/DNA co-
precipitation procedure as previously described [10]. For transient transfec-
tions, cells were harvested 48 h post transfection. To create HEK 293 cellFig. 1. Schematic of the carboxyl (C) tail domain of TPα. The amino acid
sequence of the carboxyl terminal (C)-tail domain of TPα (residues 321–
343) is shown, where residues unique to TPα (residues 329–343) are
underlined. The truncation (Δ) mutant TPαΔ336, generated by conversion of
Leu336 codon to a stop codon, is indicated by the open arrow head while
Ser/Thr to Ala substitutions to generate TPαS329A, TPαS331A, TPαT337A and
TPαT340A mutations are indicated by the solid arrows. The combination
substitutions TPαS329,331A, TPαS331,T337A, TPαS331,340A, TPαT337,S340A and
TPαS331,T337,S340A were also generated. Mutations involving Ser145 or Ser239
within IC2 or IC3, respectively, either alone or in combination with the C-tail
mutations are not shown.lines stably over-expressing HA-epitope tagged forms of TPαS145A (HEK.
TPαS145A), TPS145A,Δ328 (HEK.TPS145A,Δ328), TPαS239A (HEK.TPαS239A),
TPαS340A (HEK.TPαS340A), TPαS331,T337A (HEK.TPαS331,T337A), TPαS331,340A
(HEK.TPα
S331,340A
), TPαT337,S340A (HEK.TPαT337,S340A), TPαS331,T337,S340A
(HEK.TPαS331,T337,S340A), TPαS134,S331,T337 A (HEK.TPαS145,S331,T337A),
cells were transfected with 10 μg of Sca1-linearised pADVA plus 25 μg of
the appropriate Pvu1-linearised pHM6-based recombinant plasmids. Forty-
eight hours post-transfection, G418 (0.8 mg/ml) was applied and after
approximately 21 days, individual G418-resistant colonies were selected and
individual pure clonal stable cell lines/isolates were examined for TP
expression by analysis of radioligand binding.
2.4. Radioligand binding studies
Cells were harvested by centrifugation at 500×g at 4 °C for 5 min and
washed three times with ice-cold Ca2+/Mg2+-free phosphate-buffered saline
(PBS). TP radioligand binding assays were carried out at 30 °C for 30 min in
100 μl reactions in the presence of 0–40 nM [3H] SQ29,548 for Scatchard
analysis or in the presence of 20 nM [3H] SQ29,548 for saturation radioligand
binding experiments as previously described [10]. Protein determinations were
carried out using the Bradford assay [41].
2.5. Measurement of intracellular calcium ([Ca2+]i) mobilization
Measurement of intracellular calcium mobilization ([Ca2+]i) in FURA2/
AM preloaded HEK 293 cell lines (2×106 cells/dish), each transiently co-
transfected with pADVA (10 μg), and pCMV:Gαq (25 μg), was carried out as
previously described [10]. To investigate the effect of GRK2/βARK1 on TP-
mediated [Ca2+]i mobilization, HEK.TPα or HEK.TPβ cells (2×10
6 cells/dish)
were co-transfected with pADVA (10 μg), pCMV:Gαq (25 μg) along with
pRK5:βARK1495–689 (25 μg), encoding a dominant negative form of GRK2/
βARK1[39]. Approximately 48 h post-transfection, cells were harvested by
scraping, washed twice in ice-cold PBS and resuspended in HBSSHB
(modified Ca2+/Mg2+-free Hank's buffered salt solution, containing 10 μM
HEPES, pH 7.67, 0.1% bovine serum albumin (BSA)) buffer at 107 cells/ml
and incubated in the dark with 5 μM FURA2/AM for 45 min at 37 °C. Cells
were collected by centrifugation (900×g, 5 min), washed once in an equal
volume of HBSSHB, and were finally resuspended in HBSSHB buffer at 107
cells/ml and kept at room temperature in the dark for 40 min. For each
measurement of [Ca2+]i mobilization, aliquots of cells were diluted to
0.825×106 cells/ml in HBSSHB, 1 mM CaCl2 and FURA2 fluorescence was
recorded (2 ml aliquots of cells) at 37 °C with gentle stirring with a Perkin
Elmer-Cetus LS50-B spectrofluorometer at excitation wavelengths of 340 nm
and 380 nm and emission wavelength of 510 nm, respectively.
Cells were stimulated with the TP agonist U46619 (1 μM) and changes in
[Ca2+]i mobilization were monitored as a function of time. To assess agonist-
mediated homologous desensitization, cells (0.825×106 cells/ml; 2 ml per assay)
were stimulated with 1 μM U46619 (Primary stimulation) or, as a control, with
the vehicle for 4 min; thereafter, cells were collected by centrifugation (900×g,
5 min); were washed twice in 2 ml HBSSHB, 1 mM CaCl2; and finally
resuspended in 2 ml HBSSHB,1 mMCaCl2 and were left to recover over various
time intervals (ranging from 0 to 60 min); thereafter, cells re-stimulated with
1 μMU46619 (Secondary stimulation) and changes in [Ca2+]i mobilization were
monitored as a function of time. To assess the role of protein kinase (PK) A, PKC
or PKG on U46619-mediated desensitization of TPα signalling, cells were pre-
incubated with the PKA inhibitor H-89 (10 μM), the PKC inhibitor GF 109203X
(50 nM) or the PKG inhibitor KT 5823 (50 nM), for 15 min and respective kinase
inhibitors were maintained throughout the primary/secondary U46619-stimula-
tions and during the washes. To assess the role of the nitric oxide (NO) pathway
on U46619-mediated desensitization of TPα signalling, cells were pre-incubated
with the NO synthase inhibitor L-NAME (1 μM) or the soluble guanylate cyclase
(sGC) inhibitor LY 83583 (1 μM) for 15 min and respective inhibitors were
maintained throughout the primary/secondary U46619-stimulations and during
the washes.
In all cases, the drugs (agonist or inhibitors in 0.01%ethanol inHBS)were diluted
in the vehicleHBSSHBsuch that addition of 20μl of the diluted drug/inhibitor to 2ml
of cells resulted in the correct working concentration. The vehicle had no effect on
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each sample by adding 0.2% Triton X-100 to obtain the maximal fluorescence ratio
(Rmax) and then 1 mM EGTA to obtain the minimal fluorescence ratio (Rmin). The
ratio of the fluorescence at 340 nm to that at 380 nm is a measure of [Ca2+]i [42],
which assumes a Kd of 225 nM Ca
2+ for FURA2/AM. The results presented in the
figures are representative data from at least three or four independent experiments
and are plotted as changes in Ca2+i mobilized (Δ[Ca
2+]i (nM)) as a function of time
(s) upon ligand stimulation. Changes in [Ca2+]i mobilization were determined by
measuring peak rises in [Ca2+]i mobilized (Δ[Ca
2+]i) and were calculated as mean
changes in Δ[Ca2+]i±S.E.M. (nM).
2.6. Measurement of IP3 levels
Intracellular IP3 levels were measured as previously described [33,43].
Briefly, cells were harvested by scraping, washed twice in ice-cold PBS and
resuspended at approximately 2×106 cells/200 μl in HEPES-buffered saline
(HBS; 140 nM NaCl, 4.7 mM KCl, 2.2 mM CaCl2, 1.2 mM KH2PO4, 11 mM
glucose, 15mMHEPES–NaOH, pH 7.4), 10mMLiCl (Walsh et al., 2000). Cells
(200 μl) were pre-incubated in HBS buffer at 37 °C for 10min; where appropriate
inhibitors (H-89, 10 μM; GF 109203X, 50 nM; KT 5823, 50 nM; L-NAME,
1 μM; LY 83583, 1 μM) or vehicle (HBS) were added to the cells and pre-
incubated at 37 °C for 15 min. Thereafter, cells were stimulated with 1 μM
U46619 at 37 °C for 2 min. To assess agonist-mediated homologous
desensitization, cells (2×106 cells/200 μl) were stimulated with 1 μM U46619
at 37 °C for 2 min (Primary stimulation); thereafter, cells were collected by
centrifugation (900×g, 5 min); were washed once in 200 μl HBS, 10 mM LiCl
and finally resuspended in 200 μl HBS, 10 mM LiCl and were left to recover for
60 min; thereafter, cells were re-stimulated with 1 μMU46619 at 37 °C for 2 min
(secondary stimulation). All ligands and kinases were pre-diluted in HBS such
that 50 μl added to 200 μl of cell suspension in HBS gave the desired final
concentration. To determine basal IP3 levels, an equivalent volume (50 μl) of the
vehicle HBS was added instead of ligand. The level of IP3 produced was
quantified by radio competition assay essentially as described [43]. Levels of IP3
produced by ligand stimulated cells over basal stimulation, in the presence of
HBS, were expressed in pmol IP3/mg protein±S.E.M. and as fold stimulation
over basal (fold increase±S.E.M.). In all cases, 4 independent experiments were
performed, each in duplicate.
2.7. Measurement of agonist-mediated TP phosphorylation
Agonist-mediated TP phosphorylation in whole cells (1.8–2×106 cells/
10 cm dish) was performed essentially as previously described [33]. Briefly, cells
were transiently co-transfected with pADVA (10 μg), pCMV:Gαq (25 μg) plus
pcDNA:βArrestin2 (25 μg) approximately 48 h prior to labelling. Thereafter,
cells were washed once in phosphate-free DMEM, 10% dialysed FBS and were
metabolically labelled for 60 min in the same medium (2 ml/10 cm dish)
containing 100 μCi/ml [32P] orthophosphate (8000–9000 Ci/mmol) at 37 °C, 5%
CO2. Where appropriate, the PKG kinase inhibitor KT 5823 (50 nM) or its
vehicle was added during the labelling period. Thereafter, U46619 (1 μM) or an
equivalent volume of vehicle (0.01% ethanol in HBS; 20 μl) were added and cells
were incubated for 10 min at 37 °C, 5% CO2. Reactions were terminated by
transferring the dishes to ice and aspirating the labelled medium and HA-epitope
tagged TP receptors were processed and immunoprecipitated using the anti-HA
101R antibody as previously described [33]. Electroblots were then exposed to
Xomat XAR (Kodak) film to detect 32P-labelled proteins. Thereafter, blots were
subject to phosphorimage analysis, and the intensities of agonist-induced
phosphorylation were expressed in arbitrary units relative to basal (vehicle-
stimulated) levels. In parallel experiments, cells were incubated under identical
conditions in the absence of [32P] orthophosphate; HA-tagged TP receptors were
immunoprecipitated from the same cell lines using the anti-HA 101R antibody
and immunoblots were screened using the anti-HA 3F10 horseradish peroxidase-
conjugated antibody [33].
2.8. Analysis of NOS expression and eNOS phosphorylation
RNA extracted fromHEK 293 cells (1.4 μg in 25 μl reactions) were converted to
first strand (1°) cDNA using MMLV RT essentially as previously described [18].Aliquots (3.5 μl) of each 1° cDNA were then used as templates in PCR reactions
(25 μl) using forward (F) and reverse (R) primer pairs selective for human
endothelial (e) nitric oxide synthase, (F-[5′-CCA GCTAGC CAA AGT CAC CAT-
3′], R-[5′-GTC TCG GAG CCATAC AGG ATT-3′], amplicon 354 bp; [44–46]);
neuronal (n)NOS, (F-[5′-TTG GGG GCC TGG GAT TTC TGG-3′], R-[5′CGT
TGG CAT GGG GGA GTG AGC-3′], amplicon 465 bp; [47]) and inducible (i)
NOS, F-[5′-GAG GAA GTG GGC AGG AGA ATG-3′], R-[5′-GTA GTA GAA
AGG GGA CAG GAC-3′], amplicon 294 bp; [48,49]). For each primer pair, PCRs
carried out in the absence of template served as controls. For western analysis,
aliquots of total HEK 293 cell protein were analysed by SDS-PAGE; blots were
screened versus anti-eNOS antibody (Transduction Laboratories) following by
chemiluminescence detection, essentially as previously described [33].
In order to assess eNOS phosphorylation, HEK.TPα, HEK.TPβ or HEK 293
cells (2×106 cells/10-cm dish) were plated some 48 h prior to experimentation.
Cells were incubated with vehicle, 1 μM U46619 or 10 U/ml Thrombin for
5 min at 37 °C and aliquots of whole cell protein (100 μg/lane) were analysed by
SDS-PAGE/western blot. Blots were initially screened using the anti-phospho
eNOS1177 as per supplier's instructions (Cell Signalling Technology) and,
following stripping, were subsequently re-screened using the anti-eNOS
(Transduction Laboratories).
2.9. Data analysis
Radioligand binding and Scatchard analysis data were analysed using
GraphPad Prisim V4.0 programme (GraphPad Software Inc., San Diego CA,
USA). Statistical analyses were carried out using the unpaired Student's t test
using the Statworks Analysis Package. p-values≤0.01 indicated statistically
significant differences.3. Results
3.1. Effect of primary and secondary agonist stimulation on
TPα-signalling
We have recently investigated the mechanism of agonist-
induced homologous desensitization of signalling by the
TPβ isoform of the human thromboxane (TX) A2 receptor
[50]. Herein, the aim of the current study was to investigate
the mechanism of homologous desensitization of signalling
by the TPα isoform of that receptor. We initially inves-
tigated desensitization of TPα signalling ([Ca2+]i mobiliza-
tion and IP3 generation) in response to the TXA2 mimetic
U46619 by comparing it to that of the previously cha-
racterised TPΔ328 [50], a truncated variant devoid of the
divergent residues within the C-tail domains of TPα and
TPβ [26,33].
Stimulation of HEK.TPα cells, stably over-expressing TPα
(Table 1), with the TXA2 mimetic U46619 resulted in efficient
mobilization of intracellular calcium ([Ca2+]i, Fig. 2A),
consistent with previous findings [26,33]. Pre-stimulation of
HEK.TPα cells with U46619 almost completely desensitized
TPα signalling following agonist-washout and secondary re-
stimulation at 15 min following the initial U46619 stimulation
(Fig. 2B, p=0.0001). Moreover, U46619-desensitization of
TPα signalling was sustained and did not significantly recover
even at 60 min following the primary stimulation (Fig. 2C,
p=0.0001). On the other hand, pre-treatment of HEK.TPα cells
with the vehicle, as opposed to U46619 itself, during the
primary stimulation followed by washout confirmed that the
cells retained the ability to fully signal in response to subsequent
stimulation with U46619 (Fig. 2C, inset). Hence the loss of the
Table 1
Cell lines Kd
(nM±S.E.M.)
Bmax
(pmol/mg protein±S.E.M.)
HEK.TPαWT 10.5±1.1 4.52±0.05
HEK.TPΔ328 7.2±4.1 4.47±0.04
HEK.TPαS145A 6.1±1.3 3.03±0.04
HEK.TPS145A,Δ328 6.1±3.7 3.83±0.03
HEK.TPαS239A 6.3±2.4 4.35±0.04
HEK.TPαS329A 7.1±3.2 4.43±0.04
HEK.TPαS331A 6.3±1.2 4.00±0.04
HEK.TPαΔ336 7.8±2.1 4.43±0.04
HEK.TPαT337A 6.5±1.7 4.23±0.04
HEK.TPαS340A 8.1±2.4 5.3±0.04
HEK.TPαS329,331A 8.2±1.65 2.9±0.19
HEK.TPαT337,S340A 7.5±5 4.9±0.04
HEK.TPαS331,T337A 6.9±3.1 3.23±0.03
HEK.TPαS331,T337,S340A 6.3±4 4.01±0.05
HEK.TPβWT 9.9±0.5 3.64±0.03
Scatchard analysis of HEK 293 cells stably over expressing HA-epitope tagged
forms of TPα or TPβ or their variant receptors were carried out in the presence
of the TP antagonist [3H]SQ29,548 (50.4 Ci/mmol, 0–40 nM) using 75 μg
whole cell protein/assay. Radioligand binding data were analysed with the
Graphpad prism V 3.0 computer program (GraphPad Software Inc.) to
determine the Kd and Bmax values. Data are presented as the mean values of
four independent experiments±standard error mean (S.E.M.). HEK 293 control
cells expressed 154±4.1 fmol [3H]SQ 29,548/mg protein±S.E.M. (n=3).
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during agonist-washout per se but rather resulted from agonist-
induced desensitization of TPα signalling.
While primary simulation of HEK.TPΔ328 cells also led to
efficient U46619-induced [Ca2+]i mobilization (Fig. 2D), consis-
tent with previous data [50] pre-stimulation with U46619 only
partially desensitized [Ca2+]i mobilization by TP
Δ328 such that
∼80% of its primary U46619-response occurred following its
restimulation at 15 min (Compare Fig. 2D versus Fig. 2E, p=0.2).
Moreover, desensitization of U46619-mediated [Ca2+]i mobiliza-
tion by TPΔ328 was transient such that its signalling had fully
recovered showing no desensitization at 60 min (Compare Fig. 2D
versus Fig. 2F; p=0.22). Consistent with these data, primary
stimulation of HEK.TPα and HEK.TPΔ328 cells with U46619 also
yielded efficient increases in IP3 generation (Figs. 2G and H,
respectively). While pre-incubation with U46619 almost comple-
tely inhibited IP3 generation by TPα following its secondary
restimulation (Fig. 2G, p=0.0049), it had no significant effect on
IP3 generation by TP
Δ328 at 60 min following the primary
stimulation (Fig. 2H, p=1). Moreover, similar agonist-induced
desensitization of [Ca2+]i mobilization and IP3 generation occurred
when I-BOP was used as the TP-stimulatory ligand (data not
shown). Taken together these data confirm that like TPβ, TPα is
subject to near complete and sustained agonist-induced homo-
logous desensitization while, consistent with previous reports [50],
TPΔ328 undergoes partial and transient desensitization suggesting
that the major target site(s) involved in homologous desensitization
of TPα may be located within its unique C-tail domain.
To investigate whether the second messenger-regulated
protein kinases (PKs) may play a role in mediating homologous
desensitization of TPα, the effects of the PKA and PKC
inhibitors H-89 and GF 109203X, respectively, on U46619-
induced [Ca2+]i mobilization were investigated. Pre-incubationof HEK.TPα or HEK.TPΔ328 cells with H-89 had no significant
effect on [Ca2+]i mobilization in response to their primary or
secondary stimulation with U46619 (Fig. 3A and C, respec-
tively). Whilst pre-incubation with GF 109203X had no
significant effect on [Ca2+]i mobilization by TPα or TP
Δ328 in
response to primary agonist stimulation (Fig. 3B and D,
respectively), it partially and significantly impaired desensitiza-
tion of TPα such that in the presence of GF 109203X,
secondary U46619 stimulation of TPα yielded a response of
36% relative to that of its primary response (Compare Fig. 3A
and B, primary and secondary stimulations). Consistent with
previous reports [50], pre-incubation of HEK.TPΔ328 cells with
GF 109203X fully impaired agonist-induced desensitization in
response to its secondary U46619 stimulation (Compare Fig. 3C
versus Fig. 3D, secondary responses).
Hence, it is evident that TPΔ328 undergoes partial and
transient desensitization that occurs through a GF 109203X-
sensitive, PKC mechanism, whilst TPα undergoes almost
complete and more sustained desensitization that is also
partially sensitive to GF 109203X/PKC inhibition. As TPΔ328
is devoid of C-tail residues of both TPα and TPβ, it is evident
that its target PKC-sensitive site(s) is located at sites other than
within the C-tail domain of TPα or TPβ. In fact through
computational analysis of the amino acid sequence of TPΔ328
we identified a putative PKC site within the second intracellular
loop (IC)2 where Ser
145 represents the predicted phospho-target
residue [51]. Moreover, through site-directed mutagenesis of
both TPΔ328 and TPβ, to generate TPS145A,Δ328 and TPβS145A ,
respectively, we have previously established that Ser145 actually
corresponds to the GF 109203X-sensitive, PKC site that
accounts for the partial agonist-induced desensitization of
both TPΔ328 and TPβ [50]. Hence, herein, to investigate if
Ser145 within the IC2 of TPα had any role to play in its
homologous desensitization, site-directed mutagenesis was
used to generate TPαS145A. Primary stimulation of HEK.
TPαS145A cells (Kd: 6.1±1.3 nM SQ29,548; Bmax: 3.03±
0.04 pmol/mg protein; Table 1) with U46619 resulted in
efficient [Ca2+]i mobilization (Fig. 3E) and IP3 generation (data
not shown) confirming that the mutation per se did not affect
the basic ligand binding or signalling properties of TPαS145A.
However, unlike the wild type TPα (Fig. 3E), pre-stimulation
with U46619 did not fully desensitize signalling by TPαS145A
such that secondary agonist restimulation yielded a response of
24% relative to the primary response (Fig. 3E). Similar data
were obtained when agonist-induced IP3 generation was
analysed (data not shown). Consistent with previous reports,
pre-stimulation of TPS145A,Δ328 with U46619 did not desensi-
tize [Ca2+]i mobilization in response to its secondary stimula-
tion with U46619 at 15 min following the initial stimulation
(Fig. 3F, compare primary and secondary stimulations; p= 0.55).
Taken together, these data confirm that whilst Ser145 within IC2
represents the phospho-target residue involved in partial
U46619-induced, GF 109203X-sensitive homologous desensi-
tization of TPΔ328 [50], similar to that of TPβ, Ser145 also plays
a minor though significant role in the homologous desensitiza-
tion of TPα. However, the major determinant(s) of U46619-
induced desensitization of TPα signalling appear to be located
Fig. 2. U46619-mediated desensitization of signalling by TPα. Panels A–F: HEK.TPα (Panels A–C) or HEK.TPΔ328 (Panels D–F) cells, transiently co-transfected
with pCMV:Gαq, were stimulated with 1 μM U46619 for 4 min as primary stimulation (Panels A and D). Thereafter, cells were washed to remove the U46619 as
indicated by the horizontal arrow and were then re-stimulated with 1 μM U46619 either 15 min (Panels B and E) or 60 min (Panels C and F) following the primary
U46619 stimulation, where ligands were added at the times indicated by the vertical arrows. Panel C, inset: HEK.TPα cells were stimulated with vehicle for 4 min as
the initial primary stimulation (data not shown) prior to washout and subsequent stimulation with 1 μM U46619 at 60 min. Data presented are plotted as changes in
intracellular Ca2+ mobilization (Δ[Ca2+]i, nM) as a function of time (second, s). Actual mean changes in U46619-induced [Ca
2+]i mobilization (nM ± S.E.M.) were as
follows: Panel A: Δ[Ca2+]i=174±8.8 nM; Panel B: Δ[Ca
2+]i=0 nM; Panel C: Δ[Ca
2+]i=0 nM; Panel C inset: Δ[Ca
2+]i=191.5±25.5 nM; Panel D: Δ[Ca
2+]i=180±
5.6 nM; Panel E: Δ[Ca2+]i=158±3.8 nM; Panel F: Δ[Ca
2+]i=178±6.7 nM. Panels G and H: HEK.TPα (Panel G) or HEK.TP
Δ328 (Panel H) cells, transiently co-
transfected with pCMV:Gαq or, as controls, HEK 293 cells (Panels G and H; HEK 293) were stimulated with 1 μM U46619 for 2 min (U46619); alternatively, cells
were stimulated with 1 μMU46619 for 2 min, washed to remove the agonist and re-stimulated 60 min following the primary stimulation with 1 μMU46619 for 2 min
(U4,U4). Levels of IP3 produced in ligand-stimulated cells relative to vehicle (HBS)-treated cells (basal IP3) were expressed as fold stimulation of basal (fold increase
in IP3±S.E.M.; n=4). The asterisks indicate that the level of U46619-mediated IP3 generation was significantly reduced following secondary stimulation compared to
that of the primary stimulation, or that the level of U46619-mediated IP3 generation was significantly lower in HEK 293 cells than in each of the above cell lines where
** and *** indicates p<0.01 and p<0.001, respectively. Basal levels of IP3 in HEK.TPα (Panel G), HEK.TP
Δ328 (Panel H) and HEK 293 cells (Panels G and H) were
found to be in the range of 0.27–0.39 nmol/mg protein. Panel I: HEK.TPα cells co-transfected with pCMV:Gαq (lane 1) or the control vector pCMV5 (lane 2) were
analysed by SDS PAGE (75 μg whole cell protein analysed/lane) followed by western blot analysis using anti-Gαq antibody (Gαq/11 (C-19): S.C. 392). Data presented
is a representative immunoblot from four independent experiments. The relative position of the 46-kDa molecular size marker is indicated to the right of Panel I.
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partial role in that desensitization.
3.2. The role of GRKs in homologous desensitization of TPα
In addition to the second messenger-regulated protein
kinases, members of the G protein coupled receptor kinase
(GRK) family are widely reported to play a central role inhomologous desensitization of various GPCRs [36]. Moreover,
we have recently established that GRK2/3 plays a critical role in
the homologous desensitization of signalling by TPβ [50].
Hence, herein, we investigated the role of the ubiquitously
expressed GRK2/3, also referred to as the β adrenergic kinases
(β-ARK) 1/2, in the homologous desensitization of signalling
by TPα. Initially we examined the effect of over-expressing
GRK2/βARK1495–689, a dominant-negative form of GRK2/
Fig. 3. Effect of H-89 and GF 109203X on U46619-mediated desensitization of TPα signalling. Panels A–F: HEK.TPα (Panels A and B) or, as controls,
HEK.TPΔ328 (Panels C and D) cells were pre-incubated for 10 min with either 10 μM H-89 (Panels A and C) or 50 nM GF 19203X (Panels B and D) prior
to stimulation for 4 min with 1 μM U46619 (primary stimulation; Panels A, B, C and D); cells were then washed to remove the U46619 and were then re-
stimulated at 15 min following the primary stimulation with 1 μM U46619 in the presence of 10 μM H-89 (Secondary stimulation; Panels A and C) or
50 nM GF 109203X (Secondary stimulation; Panels B and D). Data presented are representative profiles from at least four independent experiments and are
plotted as changes in intracellular Ca2+ mobilization (Δ[Ca2+]i, nM) as a function of time (second, s), where ligands were added at the times indicated by the
arrows. Actual mean changes in U46619-induced [Ca2+]i mobilization (nM±S.E.M.) in response to primary and secondary U46619-stimulations were: Panel
A: Δ[Ca2+]i=220±9.2 nM, 0 nM; Panel B: Δ[Ca
2+]i=250±12 nM, 90±8 nM; Panel C: Δ[Ca
2+]i=180±10 nM, 165±8 nM; Panel D: Δ[Ca
2+]i=200±
9.8 nM, 200±12 nM. Panels E and F: HEK.TPαS145A (Panel E) or HEK.TPS145A,Δ328 (Panel F) cells were stimulated for 4 min with 1 μM U46619 (Primary
stimulation; Panels E and F); thereafter, cells were washed and re-stimulated at 15 min following the primary stimulation with 1 μM U46619 (Secondary
stimulation; Panels E and F). Actual mean changes in U46619-induced [Ca2+]i mobilizations (nM±S.E.M.) in response to primary and secondary U46619-
stimulations were: Panel E: Δ[Ca2+]i=157±3.8 nM, 37±4.2 nM; Panel F: Δ[Ca
2+]i=174±7.7 nM, 170±9.9 nM.
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comparing it to its effect on TPβ signalling, acting as a
reference. Transient over-expression of βARK1495–689 had no
significant effect on primary U46619-induced [Ca2+]i mobiliza-
tion by TPα or TPβ (Fig. 4A and C, respectively). However,
while over-expression of βARK1495–689 almost fully impaired
desensitization of TPβ signalling following its secondary
stimulation with U46619 (Compare Fig. 4C versus Fig. 4D,
p=0.0001), it had no effect whatsoever on agonist-induceddesensitization of signalling by TPα (Compare Fig. 4A versus
Fig. 4B). Thus, while GRK2/3 (βARK1/2) play a major role in
the homologous desensitization of TPβ they do not appear to
participate in desensitization of TPα.
As Ser239 has been identified as a critical site in the GRK2/
3-mediated homologous desensitization of TPβ [50], a site
that is also common to and found within the IC3 domain of
TPα but is clearly not targeted through GRK2/3 (Fig. 4B), we
extended our studies to investigate whether it may have any
Fig. 4. Role of GRK2/3 on U46619-mediated desensitization of signalling by TPα and TPβ. HEK.TPα (Panels A and B), HEK.TPβ (Panels C and D) or HEK.
TPαS239A (Panels E and F) cells each transiently co-transfected with either pCMV:Gαq plus pRK5:βARK1495–689 (+GRKDN) or, as controls, with pCMV:Gαq plus
pRK5 (−GRKDN) were stimulated with 1 μM U46619 for 4 min (Panels A, C and E). Thereafter, cells were washed as indicated by the horizontal arrow and re-
stimulated at 15 min following the primary stimulation with 1 μMU46619 (Panels B, D and F), where ligands were added at the times indicated by the vertical arrows.
Actual mean changes in U46619-induced [Ca2+]i mobilization (nM±S.E.M.) were: Panel A: +GRK
DN, Δ[Ca2+]i=150±7.5 nM; −GRKDN, Δ[Ca2+]i=165±9 nM;
Panel B: +GRKDN,Δ[Ca2+]i=0 nM; −GRKDN,Δ[Ca2+]i=0 nM; Panel C: +GRKDN,Δ[Ca2+]i=195±11 nM; −GRKDN,Δ[Ca2+]i=180±6.7 nM; Panel D: +GRKDN,
Δ[Ca2+]i=210±12 nM; −GRKDN, Δ[Ca2+]i=0 nM. Panel E: +GRKDN, Δ[Ca2+]i=180±9 nM; −GRKDN, Δ[Ca2+]i=176±10.3 nM; Panel F: +GRKDN,
Δ[Ca2+]i=0 nM; −GRKDN, Δ[Ca2+]i=0 nM.
977L.P. Kelley-Hickie et al. / Biochimica et Biophysica Acta 1773 (2007) 970–989role to play in homologous desensitization of TPα, such as
through phosphorylation by other members of the GRK
family or other Ser/Thr kinases. Hence, site directed
mutagenesis was used to generate TPαS239A, thereby disrupt-
ing the phospho-target. Primary stimulation of HEK.TPαS239A
cells (Kd: 7.1±3.2 nM SQ29,548; Bmax: 4.35±0.04 pmol/mg
protein; Table 1) with U46619 resulted in efficient [Ca2+]i
mobilization (Fig. 4E) and IP3 generation (data not shown)
confirming that the mutation per se did not affect the basic
ligand binding or signalling properties of TPαS239A. Similar to
that of the wild type TPα (Fig. 2A and B), pre-stimulation
with U46619 fully desensitized signalling by TPαS239A (Fig.
4E and F). Moreover, over-expression of the dominant
negative βARK1495–689 had no effect on the primary
signalling or on the level of agonist-induced homologous
desensitization of TPαS239A (Fig. 4E and F, +GRK DN).
These data clearly indicate that while Ser239 within IC3 is acritical GRK2/3-targeted site in the homologous desensitiza-
tion of TPβ signalling, that site appears to be redundant in
TPα and does not participate in desensitization of signalling
of TPα.
3.3. Investigation of the role of the unique C-tail domain in
homologous desensitization of TPα.
Hence, it is evident that while Ser145 within the IC2 domain
plays a role, at least in part, in the GF 109203X, PKC-dependent
homologous desensitization of signalling by TPα, from studies
with TPΔ328 it appears that the major determinants of
TPα desensitization rely on sequences within its unique C-tail
domain. Analysis of the C-tail sequence of TPα reveals several
Ser/Thr residues that might represent target sites for agonist-
induced phosphorylation or desensitization, including Ser329,
Ser331, Thr337 and Ser340 (Fig. 1). Thus, Ala-scanning and/or
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targets either individually to generate TPαS329A, TPαS331A,
TPαΔ336, TPαT337A and TPαS340A or, there after, in various
specific combinations as relevant. It is noteworthy that Ser329 has
previously been identified as a target residue for PKA phosphor-
ylation [33] while Ser331 was identified as a target for PKG
phosphorylation [35] and Thr337 as a target for PKC phosphoryla-tion [32]. Initially, Scatchard analyses confirmed that values
obtained for the affinity (Kd) and maximal radioligand binding
(Bmax) for each of the HEK 293 cell lines stably over-expressing
the respective variant receptors compared well to those
previously reported for wild type TPα (Table 1) and clearly
indicated that the mutations per se did not affect their ligand
binding properties.
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mobilization and IP3 generation in response to U46619 (Fig. 5A
and C). Moreover, pre-stimulation of HEK.TPαS329A cells with
U46619 completely desensitized [Ca2+]i mobilization and IP3
generation in response to secondary agonist stimulation (Fig.
5A–C). These data concur with previous results using H-89
demonstrating that the PKA inhibitor H-89 had no effect on the
homologous desensitization of TPα (Fig. 3A).
Consistent with previous reports [35], agonist stimulation of
TPαS331A yielded efficient [Ca2+]i mobilization and IP3 generation
(Fig. 5D and F). Pre-stimulation of HEK.TPαS331A cells with
U46619 impaired, but did not fully abolish [Ca2+]imobilization and
IP3 generation (Fig. 5D–F) in response to secondary stimulation
with U46619. Specifically, the level of [Ca2+]i mobilization by
TPαS331A following secondary stimulation corresponded to 39%of
that mobilized following primary U46619 stimulation. These data
suggest that Ser331 plays a significant role in the homologous
desensitization of TPα.
U46619-stimulation of TPαΔ336, a truncated variant of TPα
eliminating two potential target phosphorylation sites at Thr337
and Ser340, yielded efficient [Ca2+]i mobilization and IP3
generation in response to U46619 (Fig. 5G and I, respectively).
Pre-stimulation of TPαΔ336 with U46619 impaired but did not
abolish [Ca2+]i mobilization and IP3 generation in response to its
secondary agonist stimulation (Fig. 5H and I, respectively).
Specifically, the level of [Ca2+]i mobilization by TPα
Δ336 in
response to secondary U46619 stimulation corresponded to 20%
of its response (compare Fig. 5G versus Fig. 5H, p< 0.0003).
Moreover, while both TPαT337A (Fig. 5J and L, respectively) and
TPαS340A (Fig. 5M and N, respectively) yielded efficient [Ca2+]i
mobilization and IP3 generation in response to primary stimula-
tion, signalling by TPαS340A was fully desensitized following
secondary U46619-stimulation (Fig. 5M–O) while that of
TPαT337A was only partially desensitized (Fig. 5J–L). Specifi-
cally, the level of [Ca2+]i mobilization by TPα
T337A in
response to secondary stimulation corresponded to 25% of
that of its primary response. These data suggest that Thr337, a
site previously established to act as a PKC site [32], plays a
significant role in the homologous desensitization of TPα and
are consistent with findings herein indicating that desensitiza-
tion of TPα is sensitive to the PKC inhibitor GF 109203X
(Fig. 3B).Fig. 5. Role of the C-tail domain in agonist-induced desensitization of TPα signalling
E), HEK.TPαΔ336 (Panels G and H), HEK.TPαT337A (Panels J and K) or HEK.TPαS34
with 1 μM U46619 for 4 min as primary stimulation (Panels A, D, G, J and M). The
arrow and were then re-stimulated 15 min following the primary stimulation with 1
indicated by the vertical arrows. Data presented are plotted as changes in intracellular
changes in U46619-induced [Ca2+]i mobilization (nM±S.E.M.) were as follows: Pa
207±9.1 nM; Panel E:Δ[Ca2+]i=80±6.8 nM; Panel G:Δ[Ca
2+]i=240±14 nM; Pane
49±5 nM, Panel M: Δ[Ca2+]i=180±6.1 nM; Panel N: Δ[Ca
2+]i ±0 nM. Alternativel
HEK.TPαT337A (Panel L), or HEK.TPαS340A (Panel O) cells, co-transfected with pCM
U46619); cells were then washed and re-stimulated at 60 min following the primary
controls, HEK 293 cells were stimulated for 2minwith 1μMU46619 (Panels C, F, I, L
vehicle (HBS) treated cells (basal IP3) were expressed as fold stimulation of basal (fol
mediated IP3 generationwas significantly reduced following secondary stimulation com
generation was significantly lower in HEK 293 cells than in each of the above cell lines
levels of IP3 in the latter cell lines were found to be in the range of 0.27±0.06–0.39Hence, taken collectively, our data generated from the
systematic Ala-scanning mutagenesis studies indicate a specific
role for Ser145 located in IC2, Ser
331 and Thr337 located within the
C-tail domain in the agonist-induced desensitization of TPα, with
no apparent role for Ser239 within IC3 or Ser
329 or Ser340 in that
desensitization. Thereafter, to exclude the possibility that the latter
sites might act in concert or in synergy with the former sites in
contributing to the desensitization of signalling of TPα, site-
directed mutagenesis was used to disrupt those sites in specific
combinations (Table 1). Initially we investigated the role of Ser239
in combination with Ser331 or Thr337 to generate TPαS239,331A and
TPαS239,T337A, respectively. While primary stimulation of
TPαS239,331A with U46619 yielded efficient increases in [Ca2+]i
mobilization and IP3 generation (Fig. 6A and data not shown), the
level of its agonist-induced desensitization was not significantly
different to that of TPαS331A (compare Fig. 6B versus Fig. 5E,
respectively). Specifically, the level of [Ca2+]i mobilization by
TPαS239,331A in response to secondary stimulation corresponded to
36% of the primary U46619 response. Moreover, mutation of
Ser239 in combination with Thr337 to generate TPαS239,T337A did
not affect the level of desensitization relative to that of TPαT337A
alone (data not shown). These data clearly indicate that mutation of
Ser239, located within IC3, in combination with either Ser
331 or
Thr337 does not affect the overall level of TPα desensitization and
hence, consistent with our previous data (Fig. 5A–C), we conclude
that Ser239 does not contribute to TPα desensitization.
Similarly, we also investigated the role of Ser340 in
combination with Ser331 or Thr337 to generate TPαS331,340A
and TPαT337,340A, respectively. While primary stimulation of
TPαS331,340A and TPαT337,340A with U46619 yielded efficient
increases in [Ca2+]i mobilization (Fig. 6C and E, respectively)
and IP3 generation (data not shown), in each case the level of
agonist-induced desensitization was not significantly different
to that of their respective single mutants TPαS331A (compare
Fig. 6D versus Fig. 5E, respectively) or TPαT337A (compare
Fig. 6F versus Fig. 5K, respectively). Collectively these data
confirm that mutation of Ser340 in combination with either
Ser331 or Thr337 does not affect the overall level of TPα
desensitization and hence, consistent with our previous data
(Fig. 5M–O), we conclude that Ser340 does not contribute to
TPα desensitization. Moreover, through a similar series of
experiments to generate TPαS329,331A and TPαS329,T337A (data. Panels A–N: HEK.TPαS329A (Panels A and B), HEK.TPαS331A (Panels D and
0A (Panels M and N) cells, each co-transfected with pCMV:Gαq, were stimulated
reafter, cells were washed to remove the U46619 as indicated by the horizontal
μM U46619 (Panels B, E, H, K and N), where ligands were added at the times
Ca2+ mobilization (Δ[Ca2+]i, nM) as a function of time (second, s). Actual mean
nel A: Δ[Ca2+]i=228±7.7 nM; Panel B: Δ[Ca
2+]i=0 nM; Panel D: Δ[Ca
2+]i=
l H:Δ[Ca2+]i=50±3.4 nM, Panel J:Δ[Ca
2+]i=200±9.2 nM; Panel K:Δ[Ca
2+]i±
y: HEK.TPαS329A (Panel C), HEK.TPαS331A (Panel F), HEK.TPαΔ336 (Panel I),
V:Gαq, were stimulated with 1 μMU46619 for 2 min (Panels C, F, I, L and O;
stimulation with 1 μM U46619 for 2 min (Panels C, F, I, L and O; U4, U4). As
andO;HEK293). Levels of IP3 produced in ligand-stimulated cells relative to the
d increase in IP3±S.E.M.; n=4). The asterisks indicate that the level of U46619-
pared to that of the primary stimulation, or that the level of U46619-mediated IP3
where *, ** and *** indicates p<0.05, p<0.01 and p<0.001, respectively. Basal
±0.09 nmol/mg protein.
980 L.P. Kelley-Hickie et al. / Biochimica et Biophysica Acta 1773 (2007) 970–989not shown), consistent with our previous data involving
TPαS329 (Fig. 5A–C) and H-89 (Fig. 3A), we also excluded a
role for Ser329 in the homologous desensitization of TPα.Thereafter, we investigated the overall effect of mutating Ser145,
Ser331 and Thr337 in combination (Table 1). Stimulation of HEK.
TPαS331,T337A cells yielded efficient [Ca2+]i mobilization (Fig. 6G)
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However, pre-stimulation with agonist only partially desensitized
signalling by TPαS331,T337A (Fig. 6G and H). Specifically, the level
of [Ca2+]i mobilization by TPα
S331,T337A in response to secondary
stimulation corresponded to 33% of that [Ca2+]i mobilized in
response to the primary U46619 stimulation. Consistent with these
data, the level of agonist-induced desensitization of TPαS331,T337,
S340A was some 34% of its primary response (compare Δ[Ca2
+]i=195±12 nM for the primary response versus Δ[Ca
2+]i=67
±8.2 nM for the secondary response; Fig. 6I and J), further
confirming a role for Ser331 and Thr337, but not Ser340, in TPα
desensitization.
Consistent with the other mutant cell lines, U46619-induced
stimulation of HEK.TPαS145,S331,T337A cells, in which Ser145
within IC2 was also mutated along with Ser
331 and Thr337, yielded
efficient [Ca2+]i mobilization confirming that the mutation per se
did not affect its basic signalling. However, pre-stimulation of
TPαS145,331,T337A with U46619 only partially desensitized that
signalling by such that its level of [Ca2+]i mobilization following
secondary agonist stimulation corresponded to 55% of its primary
response (data not shown). Thus, taken together it appears that TPα
is subject to GF 109203X-sensitive desensitization, where Ser145
and Thr337 [32] within its IC2 and C-tail domains, respectively,
have been identified as the putative PKC-phospho-targets. In
addition, Ser331, a site previously identified as a cGMP-dependent
PKG site [35] has also been found to be critical for agonist-induced
desensitization of TPα.
3.4. Agonist-induced phosphorylation of TPα in whole cells
(in vivo)
It has been previously reported that TPα is subject to rapid
agonist-induced phosphorylation that is dependent, at least in part,
on PKC activation [20,25]. Hence herein, to establish whether TPα
undergoes agonist-induced PKG phosphorylation, we investigated
the effect of KT 5823 on TPα and TPαS331A phosphorylation in
whole cells/in vivo. Initially, the specificity of the anti-HA
antibodies to immunoprecipitate TPs from the respective cell
lines, but not from the parent HEK 293 cells, was confirmed (Fig.
7C). The presence of a discrete band of approximately 39 kDa and a
broad diffuse band of 46–60 kDa representing their non-
glycosylated and glycosylated forms, respectively, were evident
in the TPα and TPαS331A immunoprecipitates (Fig. 7C, lanes 1 and
2, respectively) whilst no immunoreactive bands were evident in
immunoprecipitates prepared from non-transfected HEK 293 cells
(Fig. 7C, lane 3). Stimulation of HEK.TPα cells with U46619 led
to 5–7-fold increase in the level of TPα phosphorylation relative to
vehicle treated cells (Fig. 7A, lanes 1 and 2). Moreover, pre-Fig. 6. Role of the C-tail domain in agonist-induced desensitization of TPα signalling
and D), HEK.TPαT337,S340A (Panels E and F), HEK.TPαS331,T337A (Panels G and H),
Gαq, were stimulated with 1 μMU46619 for 4 min as primary stimulation (Panels A,
by the horizontal arrow and were then re-stimulated 15 min following the primary stim
at the times indicated by the vertical arrows. Data presented are plotted as changes in
Actual mean changes in U46619-induced [Ca2+]i mobilization (nM±S.E.M.) were
Panel C:Δ[Ca2+]i=160±7.2 nM; Panel D:Δ[Ca
2+]i=60±10 nM; Panel E:Δ[Ca
2+]i=
Panel H: Δ[Ca2+]i=60±7.1 nM, Panel I: Δ[Ca
2+]i=195±12 nM; Panel J: Δ[Ca
2+]iincubation with KT 5823 reduced the level of agonist-induced TPα
phosphorylation by 2.5 fold (Fig. 7A, lane 3). Consistent with this,
while stimulation of HEK.TPαS331A cells with U46619 led to 2.5-
fold increase in the level of TPαS331A phosphorylation relative to
basal levels in vehicle treated cells (Fig. 7B, lanes 1 and 2), agonist-
induced phosphorylation of TPαS331A was not significantly
affected by preincubation with KT 5823 (Fig. 7B, lanes 1 and 2).
Moreover, TPαS331,T337A failed to undergo significant U46619-
induced phosphorylation above basal levels (Fig. 7D).
3.5. Investigation of the role of Nitric oxide signalling in
homologous desensitization of TPα
To further address whether PKG plays an important role in
homologous desensitization of TPα, we examined the effect of
various pharmacological inhibitors of the NO/cGMP signalling
cascade on U46619-induced desensitization of TPα, and as a
control, onTPβ signalling.While pre-incubation ofHEK.TPα cells
with KT 5823 (50 nM) did not interfere with their ability to
mobilize [Ca2+]i per se (Compare Fig. 2A versus Fig. 8A), it
partially inhibited U46619-induced desensitization of TPα signal-
ling in response to secondary stimulation with U46619 (Fig. 8B).
Specifically, in the presence of KT 5823, the level of [Ca2+]i
mobilized by TPα in response to its secondary stimulation with
U46619 corresponded to approximately 38% of its primary
response (Fig. 8A and B). On the other hand, pre-incubation of
HEK.TPβ cells withKT 5823 had no significant effect onU46619-
induced [Ca2+]i mobilization in response to its primary stimulation
and did not impair agonist-induced desensitization of signalling by
TPβ (Insets to Fig. 8A and B).
A potent stimulator of PKG is the activation of nitric oxide
synthase (NOS) promoting the conversion of L-arginine to nitric
oxide. NO, in turn, activates the soluble form of guanylate cyclase
(sGC) leading to a rise in intracellular cGMP and activation of
PKG [52–55]. Hence, we also investigated the actions of sGC and
NOS inhibitors LY 83583 and L-NAME, respectively, on TPα
desensitization. While pre-incubation of TPα with LY 83583 did
not interfere with its ability to mobilize [Ca2+]i per se (Compare
Fig. 2A versus Fig. 8C), it partially inhibited desensitization of
TPα signalling (Fig. 8D). In the presence of LY83583, the level of
[Ca2+]i mobilized following secondary stimulation corresponded
to approximately 30% of its primary response. LY 83583, on the
other hand, had no significant effect on [Ca2+]i mobilization by
TPβ following its primary or secondary stimulation with U46619
(Insets to Fig. 8C and D). Similarly, the NOS inhibitor L-NAME
had no effect on primary U46619-induced signalling by TPα
(Compare Fig. 2A versus Fig. 8E) but significantly inhibited
desensitization of TPα signalling (Fig. 8E and F). Specifically, in. Panels A–J: HEK.TPαS329,331A (Panels A and B), HEK.TPαS331,340A (Panels C
or HEK.TPS331,T337,S340A (Panels I and J) cells, each co-transfected with pCMV:
C, E, G and I). Thereafter, cells were washed to remove the U46619 as indicated
ulation with 1 μMU46619 (Panels B, D, F, H and J), where ligands were added
intracellular Ca2+ mobilization (Δ[Ca2+]i, nM) as a function of time (second, s).
as follows: Panel A: Δ[Ca2+]i=176±9.4 nM; Panel B: Δ[Ca
2+]i=63±4.4 nM;
179±11 nM; Panel F:Δ[Ca2+]i=40±3.4 nM; Panel G:Δ[Ca
2+]i=181±6.5 nM;
=67±8.2 nM.
Fig. 7. U46619-mediated phosphorylation of TPα. Panels A and B: HEK.TPα (Panel A) and HEK.TPαS331A cells (Panel B), metabolically labelled with [32P]
orthophosphate, were pre-incubated for 15 min with 50 nM KT 5923 (Panels A and B, lane 3) prior to incubation for 10 min with the vehicle HBS (Panels A and B;
lane 1) or 1 μM U46619 (Panels A and B; lanes 2 and 3). Immunoprecipitates were resolved by SDS-PAGE and electroblotted onto PVDF membranes. Blots were
subject to PhosphorImage analysis and the intensities of U46619-mediated TPα phosphorylation relative to basal phosphorylation in the presence of HBS were
determined and expressed in arbitrary units as follows: TPα: 1 μM U46619, 5-fold increase; 1 μM U46619 plus 50 nM KT 5923, 2-fold; TPαS331: 1 μM U46619,
2-fold increase; 1 μMU46619 plus 50 nM KT 5923, 1.5-fold. Panel C: HEK.TPα, HEK.TPαS331A and, as a control, HEK 293 cells (Panel C, lanes 1–3, respectively)
were subject to immunoprecipitation with anti-HA antibody 101R and immunoblots screened using the anti-HA 3F10 horseradish peroxidase-conjugated antibody
followed by chemiluminescence detection. The positions of the molecular weight markers (kDa) are indicated to the left and right of the panels A and C. The arrow to
the left of Panel A indicates the approximate position of the phosphorylated TPα. Data presented are representative of three independent experiments. Panel D: HEK.
TPα , HEK.TPαS331A and HEK.TPαS331,T337A cells, metabolically labelled with [32P]orthophosphate, were stimulated for 10 min with 1 μM U46619 (+) or with an
equivalent volume of the vehicle HBS (−). Thereafter, HA epitope-tagged TPβ receptors were immunoprecipitated as previously described. Blots were subject to
PhosphorImage analysis and the intensities of U46619-mediated TPα phosphorylation relative to basal levels in the presence of HBS were determined and expressed in
arbitrary units (Phosphorylation; fold increase, n=3).
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following secondary U46619 stimulation corresponded to
approximately 40% of the primary signal. L-NAME had no
significant effect on [Ca2+]i mobilization by TPβ following its
primary or secondary signalling (Insets to Fig. 8E and F).
Thereafter we sought to establish whether any or all of the
NOS isoforms are actually expressed in HEK 293 cells. RT-PCR
permitted detection of endothelial (e)NOS and neuronal (n)NOS
but not inducible (i)NOS transcripts (Fig. 9A) and western blot
analysis also confirmed the abundant endogenous expression of
eNOS (Fig. 9B) in that cell line. Moreover, consistent with the
role of NO/PKG in agonist-induced desensitization of TPα,stimulation of HEK.TPα cells (Fig. 9C) or indeed non-
transfected HEK 293 or HEK.TPβ cells (data not shown) with
U46619 (1 μM, 5 min) led to the rapid phosphorylation-
dependent activation of eNOS, as detected using the anti-
phospho eNOSSer1177 antisera (Fig. 9C). In fact the level of
eNOS phosphorylation in response to U46619 was comparable,
if not greater, than those levels detected in response to
stimulation of cells with thrombin (Fig. 9C), an agent that has
recently been established to lead to rapid phosphorylation of
eNOS at Ser1177/1179 leading to its activation [56].
Hence taken collectively, data herein indicate that agonist-
induced densensitization of TPα signalling involves two key
Fig. 8. Effect of KT 5823, LY 83583 and L-NAME on U46619-mediated desensitization of TPα signalling. Panels A–F: HEK.TPα (Panels A–F) or, as controls,
HEK.TPβ (Insets A–F) cells were pre-incubated for 15 min with either 50 nM KT 5823 (Panels and Insets A and B), 1 μM LY 83583 (Panels and Insets C and D)
or 1 μM L-NAME (Panels and Insets E and F) prior to stimulation with 1 μM U46619 (primary stimulation; Panels and Insets A, C and E); cells were then washed
to remove the U46619 as indicated by the horizontal arrow and were then re-stimulated at 15 min following the primary stimulation with 1 μM U46619 in the
presence of 50 nM KT 5823 (Panels and Insets B), 1 μM LY 83583 (Panels and Insets D) or 1 μM L-NAME (Panels and Insets F). Data presented are representative
profiles from at least four independent experiments and are plotted as changes in intracellular Ca2+ mobilization (Δ[Ca2+]i, nM) as a function of time (second, s),
where the ligands were added at the times indicated by the arrows. Actual mean changes in U46619-induced [Ca2+]i mobilization (nM±S.E.M.) were: Panel A:
Δ[Ca2+]i=160±7.9 nM; Panel B: Δ[Ca
2+]i=60±7 nM; Panel C: Δ[Ca
2+]i=210±12 nM; Panel D: Δ[Ca
2+]i=58±6 nM; Panel E: Δ[Ca
2+]i=200±9 nM; Panel F:
Δ[Ca2+]i=80±5.9 nM. Inset A: Δ[Ca
2+]i=170±25 nM; Inset B: Δ[Ca
2+]i=0 nM; Inset C: Δ[Ca
2+]i=185±26 nM; Inset D: Δ[Ca
2+]i=0 nM; Inset E: Δ[Ca
2+]i=
220±40 nM; Inset F: Δ[Ca2+]i=0 nM.
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regulated PKC activation and phosphorylation of Ser145 and
Thr337 and another involving eNOS phosphorylation and
activation leading the NO/cGMP-regulated PKG phosphor-ylation of Ser331. Hence, in addition to the agonist-mediated
PKC-feedback mechanism, engagement of the NO-cGMP
signalling pathway through U46619-activation of the NOS/
sGC/PKG pathway plays a significant role in inducing
Fig. 9. Analysis of nitric oxide synthase (NOS) expression and activation in HEK 293 cells. Panel A: RT-PCR analysis of 1° cDNA from HEK 293 cells as template
and primer pairs to selectively amplify neuronal (n)NOS (lane 1), endothelial (e)NOS (lane 3) or inducible (i)NOS (lane 5); negative controls where individual primer
pairs were added to the reaction without template cDNA are shown in lanes 2 (nNOS), 4 (eNOS) and 6 (iNOS). Molecular weight markers are shown in lanes M, and
the position of the 350- and 517-bp markers are indicated to the left and right of the panel. PCR products corresponding to (n)NOS (lane 1; 456 bp) and (e)NOS (lane 3;
354 bp) were specifically amplified. Panel B: western blot analysis of eNOS expression. Aliquots (100 μg and 200 μg, respectively) of HEK 293 cell protein was
analysed by SDS-PAGE followed by western blot analysis using anti-eNOS antibody. The relative position of the 120-kDA marker is indicated to the left of the panel.
Results shown in Panel C: Phosphorylation of eNOS in HEK.TPα cells. HEK.TPα cells were incubated at 37 °C for 5 min with either vehicle, 1 μM U46619 or
10 U/ml Thrombin. Whole cell protein was analysed by SDS-PAGE followed by western blot analysis using anti-phospho eNOS1177 and anti-eNOS, as indicated.
The relative position of the 120-kDA marker is indicated to the left of the panel. Results shown in Panels A–C are representative of 3 independent experiments.
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293 cells.
4. Discussion
Agonist-induced homologous desensitization represents a
critical regulatory component of the integrated signalling
modality of diverse members of the GPCR superfamily and
provides a mechanism of terminating, at least in part, the
primary signalling response [29,30]. Phosphorylation of the
GPCR, typically on Ser/Thr residues within its intracellular loop
(IC) or carboxyl-terminal (C) tail domains, initiates such
desensitization uncoupling the GPCR from its cognate G-
protein(s). The G protein-coupled receptor kinases (GRKs), of
which GRK1–7 have been identified, can only phosphorylate
the agonist-engaged conformationally active GPCR and hence
are typically associated with homologous desensitization
[29,30,57]. Recruitment of β-arrestin1/2 adaptor(s) to the
GRK-phosphorylated receptor sterically hinders G-protein
coupling [30,36,58]. Moreover, depending on the GPCR, β-
arrestin recruitment may promote sequestration and internaliza-
tion of the desensitized receptor into intracellular compart-
ments, such as through clathrin- or caveolin-dependent
mechanisms [30,36,58], ultimately leading to either depho-
sphorylation and recyclization (resensitization), degradation or
recruitment of the GPCR into scaffolds/microdomains for
participation in other signalling systems [30,36,58–60]. The
second messenger-regulated kinases, such as cAMP-dependent
protein kinase (PK) A and diacylglycerol-regulated PKC, on the
other hand, can phosphorylate GPCRs even in the absence of
the specific agonist and, hence, are most frequently associatedwith heterologous desensitization or cross-talk between differ-
ent signalling systems, but may also contribute to homologous
desensitization in certain cases [29,30].
The platelet-derived prostanoid TXA2 regulates a range of
physiologic responses mainly within the vasculature and is
implicated as a mediator of a host of vascular disorders [3–
5,12,13]. TXA2 acts as a potent evanescent autocoid with an
estimated half-life of 30 s, being rapidly hydrolysed to its
inactive metabolite TXB2 [1]. However, in such cases as
thrombosis, vascular occlusion and hypertension where TXA2 is
produced in large quantities over prolonged periods [61,62],
turning off the TXA2 signal may also occur at the level of its
receptor TP [29,30,36]. TP also mediates many the actions of the
isoprostane 8-iso-PGF2α that is generated in abundance in
situations of oxidative injury [10,11]. Furthermore, in primates
TXA2 signals through two TP receptor isoforms, termed TPα
and TPβ, adding to the complexity whereby the responses to
TXA2 and, indeed, 8-iso-PGF2α may be regulated in humans.
Hence, bearing this in mind, we have recently investigated the
mechanisms whereby the cellular responses of TXA2 mediated
by the TPβ isoform of the human TXA2 receptor (TP) are
regulated and established that GRK2/3 plays a major role in that
homologous desensitization, with an additional minor role for
PKC [50]. Specifically, it was found that agonist-induced
GRK2/3 phosphorylation of Ser357 within the unique C-tail
domain of TPβ provides a docking site to recruit and orientate
GRK2/3, facilitating its phosphorylation of Ser239 within IC3,
impairing Gq coupling, desensitizing TPβ signalling and
promoting its agonist-induced internalization [50]. As TPα
and TPβ diverge within their C-tail domains, sequences such as
Ser357 determined to be critical for desensitization of TPβ are
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agonist-induced desensitization of the TP isoforms may indeed
differ. Moreover, consistent with that hypothesis, TPβ but not
TPα undergoes agonist-induced internalization largely through
a GRK/β-arrestin-dependent mechanism [37,63]. Hence, the
overall aim of the current study was to investigate the molecular
mechanism(s) whereby the cellular responses of TXA2 media-
ted by the TPα isoform are specifically regulated thereby
aiming to elucidate the mechanism of homologous desensitiza-
tion of TPα.
It was initially confirmed that, similar to TPβ, TPα was
subject to complete agonist-induced homologous desensitiza-
tion as assessed by measurement of [Ca2+]i mobilization and IP3
generation in response to the TXA2 mimetic U46619.
Desensitization of TPα is sustained showing no significant
recovery following agonist wash-out and re-stimulation some
60 min following the primary response. On the other hand and
consistent with our previous data [50], TPΔ328, the truncated
derivative devoid of the divergent residues of TPα and TPβ,
underwent partial and transient desensitization with its signal-
ling fully recovered to that of its primary response at 60 min.
Moreover, desensitization of TPΔ328 was blocked by pre-
incubation with the PKC inhibitor GF 109203X or by mutation
of Ser145 within IC2 to generate TP
S145A,Δ328 [50]. While the
PKA-inhibitor H-89 had no effect on TPα signalling, GF
109203X quite significantly impaired agonist-induced desensi-
tization such that the magnitude of the secondary U46619-
response by TPα was 36% of its primary response in the
presence of GF 109203X. Mutation of Ser145 within IC2 to
generate TPαS145A, a residue common to both TP isoforms and
previously identified as the critical PKC phospho-target of both
TPΔ328 and TPβ [50], established that the level of desensitiza-
tion of TPαS145Awas partially impaired, signalling to 24% of its
primary response following secondary agonist stimulation.
Hence, collectively these data suggested that whilst Ser145
within IC2 represents the PKC phospho-target residue involved
in transient and partial desensitization of TPΔ328 [50], similar to
that of TPβ [50] Ser145 also plays a minor though significant
role in the homologous desensitization of TPα. However, these
data also suggest that the major determinant(s) of desensitiza-
tion of TPα signalling appear to be located within its unique C-
tail domain.
As stated, GRK2/3 plays a major role in both agonist-
induced desensitization of signalling and internalization of TPβ
where Ser239 and Ser357 within the IC3 and C-tail domains,
respectively, were identified as the critical functional targets
[50]. Hence, herein, we initially investigated the role of the
ubiquitously expressed GRK2/3 in the homologous desensitiza-
tion of signalling by TPα by examining the effect of over-
expressing GRK2/βARK1495–689, a dominant negative form
that impairs GRK2/3 membrane translocation and activation
[39]. While βARK1495–689 almost fully impaired desensitiza-
tion by TPβ, it had no significant effect on primary or secondary
signalling by TPα. Moreover, mutation of Ser239 within the IC3
domain of TPα, a critical GRK2/3-target site within TPβ [50],
established that TPαS239A under-went complete agonist-
induced desensitization of signalling similar to the wild typeTPα. Collectively these data clearly indicate that while Ser239
within IC3 is a critical GRK2/3-targeted site in TPβ, it appears
to be redundant in TPα and does not participate in its
homologous desensitization and hence that residue is unlikely
to be a target for phosphorylation/desensitization by other
GRKs, such as by the ubiquitously expressed GRK5 or GRK6
[64]. It is also noteworthy that the sequences DS239E and
DS357R are identically found in both the human and chimp TPβ
sequences but neither phosphotarget sites are found in the single
bovine, mouse or rat TP orthologs suggesting that both Ser239
and Ser357 have co-evolved to confer a common function to the
TPβ isoforms in primates and clearly account for the redundant
role of Ser239, in functional terms, within the TPα primate
orthologs. The finding herein that GRK/β-arrestins do not play
a significant role in homologous desensitization of signalling by
TPα are entirely consistent with reports that TPα does not
undergo significant agonist-induced internalization [37].
Hence, while Ser145 within the IC2 domain plays a role in the
GF 109203X-sensitive, PKC-dependent homologous desensiti-
zation of signalling by TPα, from studies with TPΔ328 it was
evident that the major determinants of TPα desensitization rely
on sequences within its unique C-tail domain. The C-tail
sequence of TPα has several Ser/Thr residues that might
represent target sites for agonist-induced phosphorylation or
desensitization, including Ser329, Ser331, Thr337 and Ser340.
Moreover, several of those sites have been identified as targets
of heterologous desensitization [32–35]. Hence, Ala-scanning
and/or deletion mutagenesis was used to systematically disrupt
those putative phospho-targets either individually, to generate
TPαS329A, TPαS331A, TPαΔ336, TPαT337A and TPαS340A, or in
specific combinations as relevant and the functional conse-
quences of those mutations on ligand binding, primary
signalling and agonist-induced desensitization were investi-
gated. Through these mutational studies, it was established that
neither Ser329 nor Ser340, mutated either alone or in combina-
tion with other putative phospho-target residues, had any role to
play in the mediation of homologous desensitization of TPα. It
is noteworthy that Ser329 of TPα had been previously identified
as a target for PKA phosphorylation and heterologous
desensitization [33]. Hence, our data herein eliminating a role
for Ser329 in the homologous desensitization of TPα are in
agreement with that study [33] and with the fact that the PKA
inhibitor H-89 had no effect on the desensitization of TPα.
On the other hand, mutation of Ser331 or Thr337 alone or in
combination with each other or with Ser145 led to partial or near
complete impairment of agonist-induced desensitization of
TPα. Specifically, the level of [Ca2+]i mobilization by
TPαS331A and TPαT337A following their secondary stimulation
corresponded to 39% and 25% of their primary responses,
respectively. Moreover, secondary agonist stimulation of
TPαS331,T337A or TPαS145,S331,T337A yielded responses corre-
sponding to 33% and 55% of their primary responses,
respectively. The involvement of Thr337, a site previously
identified as a target for PKC phosphorylation [32], is consistent
with a significant role for PKC in the agonist-induced
desensitization of TPα and clearly indicates that both Ser145
and Thr337 within the IC2 and C-tail domains are functional
Fig. 10. Proposed mechanism of U46619-mediated, homologous desensitization
of TPα signalling. Ligand (U46619)-engagement of TPα stimulates Gq-
mediated PLCβ activation leading to increases in IP3 generation and
mobilization of [Ca2+]i. The latter rise in [Ca
2+]i triggers activation of
endothelial nitric-oxide synthase (eNOS) promoting conversion of L-arginine
to nitric oxide (NO). U46619-mediated TPα activation can also lead to increased
phosphorylation of eNOS at Ser1177, through an as yet unknown mechanism,
contributing to eNOS activation (not shown). NO in turn activates the soluble
form of guanylyl cyclase (sGC) leading to a rise in intracellular cGMP and, in
turn, activation of protein kinase (PK) G. PKG, in turn, phosphorylates and
inhibits signalling by TPα where Ser331 has been identified as the target residue
for PKG phosphorylation. U46619-mediated desensitization of TPα signalling
may be inhibited by the NOS inhibitor L-NAME, by the sGC inhibitor LY 83583
or by the PKG inhibitor KT5823. Additionally, TPα/Gαq/PLCβ mediated-
increase in DAG leads to activation of PKC; PKC can phosphorylate TPα at
Ser145 and Thr337 yielding partial U46619-mediated desensitization of TPα
signalling. Thus, U46619-induced homologous desensitization of TPα is
partially mediated through both PKG and PKC-catalysed mechanisms where
Ser331 and Ser145/Thr337 have been identified as the respective phospho-targets.
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that TPα, but not TPβ, is subject to desensitization in response
to the potent vasodilator nitric oxide (NO) that occurs through
direct type 1 PKG-mediated phosphorylation where Ser331 was
identified as the PKG phospho-target [35]. Hence, these studies
[35] and data herein suggested a direct role for the NO/PKG-
mediated signalling in both the heterologous and homologous
desensitization of TPα. Consistent with this, KT 5823, the
selective PKG inhibitor, significantly reduced U46619-induced
phosphorylation of TPα but had no affect on phosphorylation of
TPαS331A or TPαS331,T337A. Moreover, pre-incubation with KT
5823 reduced agonist-induced desensitization of signalling by
TPα such that in its presence the level of [Ca2+]i mobilized
following secondary agonist stimulation corresponded to ~ 38%
of the primary response. Similarly, the sGC and NOS inhibitors
LY 83583 (30%) and L-NAME (40%), respectively, yielded
significant impairments in agonist-induced desensitization of
TPα. On the other hand, consistent with previous findings that
TPβ is not a target for NO-mediated heterologous desensitiza-
tion or PKG phosphorylation [35], neither KT 5823, LY 83583
nor L-NAME had any measurable effect on TPβ signalling
following its primary or secondary agonist stimulation.
Phosphorylation of eNOS at Ser1177 (Human)/1179 (Bovine) by
phosphatidylinositol 3-kinase (PI3-K)-dependent AKT or, as
more recently demonstrated, by Gq/PLCβ/PKCδ pathway, such
as in response to vascular endothelial growth factor [65] or
thrombin stimulation, respectively [56], plays a critical role in
eNOS activation. Herein, RT-PCR and/or western blot analysis
confirmed the endogenous expression of both eNOS and nNOS
in HEK 293 cells. Moreover, agonist (U46619)-stimulation of
HEK.TPα cells, or indeed of non-transfected HEK 293 or HEK.
TPβ cells (data not shown), led to the rapid phosphorylation of
endogenous eNOS at Ser1177 to levels comparable, if not
greater, than those in response to thrombin stimulation.
Hence, based on data presented herein, we propose a model
for the mechanism of homologous desensitization of TPα
signalling, as outlined in Fig. 10. Agonist activation of TPα and
TPβ primarily couple to Gq-dependent PLCβ activation leading
to increases in IP3 generation and mobilization of [Ca
2+]i. This,
in turn, triggers the rapid and dynamic activation of Ca2+/
calmodulin-sensitive NO synthases (NOS), such as through
Ser1177 phosphorylation and activation of eNOS, promoting the
synthesis of NO from L-Arg. NO in turn activates sGC leading
to a rise in intracellular cGMP and, in turn, activation of cGMP-
dependent PKG, or cGK [54, 55]. Type 1 PKGα/β, in turn,
phosphorylates and inhibits signalling by TPα where Ser331
represents the phospho-target. As TPβ is not a target of PKG
phosphorylation [35], it is not subject to direct desensitization
by this mechanism. Additionally, TPα/Gq/PLCβ mediated-
activation of PKC can phosphorylate Ser145 and Thr337
contributing, in part, to the desensitization of TPα signalling.
Thus, agonist-induced homologous desensitization of TPα is
mediated, at least in part, through both PKG and PKC-catalysed
mechanisms where Ser331 and Ser145/Thr337 located within IC2
and C-tail domains have been identified as the respective
phospho-targets. It is noteworthy that collective mutation of
those three sites to generate TPαS145,S331,T337A did not eliminatedesensitization of TPα, clearly indicating that other factors may
also contribute to agonist-induced desensitization of TPα.
The most striking feature of the proposed mechanism of
homologous desensitization of TPα presented herein is that it
mainly involves feedback loops whereby the second messenger
kinases PKC and PKG activated in response to its primary
signalling bring about desensitization through phosphorylation
of critical residues within its IC2 and C-tail domains. The
involvement of PKC in the agonist-induced desensitization of
TPα is in keeping with studies by Spurney et al., involving the
single murine TP where it was determined that mutation of three
putative PKC phospho-Ser residues within its C-tail domain
significantly attenuated that desensitization [66]. The endogen-
ous vasodilator NO is critical for the maintenance of normal
blood pressure [67–69] and protects the blood vessel wall by
inhibiting platelet aggregation, secretion, adhesion and fibrino-
gen binding to its receptor glycoprotein IIb/IIIa [70]. Many
intracellular events involving inositol turnover and Ca2+
mobilization, that contributes to vasoconstriction and platelet
activation status for example, are regulated by the NO/cGMP
signalling cascade, mainly through the direct- or indirect-action
of PKG. Amongst the key molecular targets of NO-regulated
PKG thus far identified is the IP3 receptor [71], thereby
inhibiting PLC activation and IP3-evoked Ca
2+ release from
intracellular stores [72], IP3 receptor-associated cGMP kinase
substrate or IRAG [73,74], myosin binding substrate [75] and
the vasodilator-stimulated phosphoprotein or VASP [76].
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indirectly attenuates signalling by the thrombin/protease-
activated receptor-1 (PAR-1) through direct activation of
regulator of G-protein signalling-2 (RGS-2), increasing the
GTPase activity of Gq [77,78]. Furthermore, as stated, through
further recent studies it has been demonstrated that thrombin
can directly lead to eNOS phosphorylation at Ser1177/1179 in
bovine aortic endothelial cells in a mechanism involving Gq/
PLCβ/PKCδ phosphorylation and Ca2+-dependent activation of
eNOS [56]. Whilst our data have indeed confirmed that both
thrombin and U46619 can readily lead to eNOS phosphoryla-
tion at Ser1177 in HEK 293 cells, we have not explored whether
that eNOS activation occurs through PKCδ or through the
classic PI-3K or other mechanism [56].
Whilst our finding herein that agonist-induced desensitiza-
tion of TPα entails a closed feedback loop involving eNOS
phosphorylation/activation, NO generation and subsequent
PKG phosphorylation is a mechanism not typically associated
with homologous desensitization of GPCRs in general, it is also
in agreement with our previous studies demonstrating that TPα
is indeed a direct target of NO/PKG phosphorylation and
heterologous desensitization [35]. Moreover, increased NO
synthesis and release is known to occur in response to TXA2 in
other cell/tissue types, such as within the pulmonary micro-
vasculature where the local release of NO acts as a compensatory
mechanism in response to the proinflammatory and vasoactive
effects of TXA2 [79]. NO regulation and synthesis via activation
of the Ca2+ dependent eNOS or nNOS isozymes can occur in
response to a diverse array of agonists that signal through
GPCRs, including the widely documented bradykinin and
muscarinic acetylcholine receptors signalling pathways, in
addition to TP [70,80]. Moreover, direct physical interaction
between the bradykinin B2 receptor and eNOS yields a
reversible inhibitory complex that is readily dissociated on
ligand binding and/or elevations in [Ca2+]i, thereby providing
another counter-regulatory mechanism between GPCR/Ca2+-
and NOS/cGMP-regulated signalling systems [81]. While we
have not been able to find any evidence for a direct interaction
between eNOS and TPα, or indeed TPβ, such as through co-
immunoprecipitation studies (Reid and Kinsella, unpublished),
we cannot rule out the possibility that additional mechanisms
other than direct phosphorylation of TPα may contribute to the
PKG-, or indeed PKC-, induced desensitization of TPα. For
example, it has been demonstrated that PKG1α can be
phosphorylated both in vitro and in vivo by PKC at Thr58,
generating a partially active kinase that is more sensitive to
cGMP levels [82]. Whether TXA2-mediated PKC activation
contributes to PKG1α activation and TPα phosphorylation/
desensitization through the latter mechanism remains to be
investigated.
Hence, in summary, it is indeed evident that there are
fundamental differences in the mechanisms of homologous
desensitization of TPα and TPβ adding further to the increasing
lines of evidence that the TP isoforms may indeed have distinct
physiologic roles. A critical difference between those two
mechanisms is that agonist-mediated desensitization of TPα
does not involve its internalization while desensitization of TPβinvolves its recruitment to an intracellular compartment(s),
making it susceptible to down-regulation or, alternatively,
potentially available for participation in other signalling systems
[30,36,58–60]. The regulation of TPα signalling provides for a
dynamic shut down or desensitization of signalling of the potent
autocoid TXA2 by the counter-regulatory NO, while TPβ remains
unchecked by that mechanism. These findings coupled to the fact
that TPα, but not TPβ, is also a direct target of prostacyclin-
induced heterologous desensitization [33] provide further evi-
dence for a critical role for TPα in vascular hemostasis whilst the
role of TPβ, if any, in that essential physiologic process remains
to be defined.Acknowledgements
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